TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8277068

Group type: EXPERIMENTAL
Intervention: Heparin (15 IU/kg body weight per h) with aspirin
Number of subjects: 250

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 250
Study: 3057817

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 30927707

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 29390463

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25445732

Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (historical matched cases)
Number of subjects: 20
Study: 23895505

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1 g twice daily
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: EPA and Aspirin combination
Number of subjects: 904

Group type: COMPARATOR
Intervention: Placebo for EPA
Number of subjects: 904

Group type: COMPARATOR
Intervention: Placebo for Aspirin
Number of subjects: 904
Study: 20880282

Group type: EXPERIMENTAL
Intervention: Feeding daily to satiation (FD)
Number of subjects: 264

Group type: COMPARATOR
Intervention: No feed for 3 days, then feeding the same amount offered to the control groups for the next 3 days (NF/R controlled)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: No feed for 3 days, then feeding to apparent satiation for the next 3 days (NF/R at satiation)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Fasting and refeeding (both NF/R controlled and NF/R at satiation)
Number of subjects: 264
Study: 18997622

Group type: EXPERIMENTAL
Intervention: Thromboaspiration followed by stenting (Group I, 19 patients)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Stenting alone (Group II, 23 patients)
Number of subjects: 42
Study: 16894077

Group type: EXPERIMENTAL
Intervention: Healthy Steps for Young Children program (HS) with prenatal component
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Healthy Steps for Young Children program (HS) without prenatal component
Number of subjects: 439

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 439
Study: 15479360

Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole 30 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Oral lansoprazole 30 mg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 87
Study: 11340101

Group type: EXPERIMENTAL
Intervention: Oats diet (45 g/(4.2 MJ dietary energy. d), n = 22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control diet (n = 21)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oats diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 43
Study: 9499103

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy
Number of subjects: 10
Study: 8002763

Group type: EXPERIMENTAL
Intervention: 10-week exercise program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-exercisers (control group)
Number of subjects: 44
Study: 2530541

Group type: EXPERIMENTAL
Intervention: Cefixime alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maalox followed 30 min later by cefixime
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maalox followed 4 hours later by cefixime
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alka-Seltzer followed 30 min later by cefixime
Number of subjects: 8
Study: 1240869

Group type: EXPERIMENTAL
Intervention: Isometric‐training Group (ITG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control‐exercise Group (CEG)
Number of subjects: 52
Study: 29485319

Group type: EXPERIMENTAL
Intervention: Online mindfulness meditation intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Psychoeducational (active control) group
Number of subjects: 139
Study: 28492476

Group type: EXPERIMENTAL
Intervention: Trimble GreenSeeker® (TGS) and Holland Scientific Crop Circle™ ACS‐430 (HCCACS‐430) sensors used to predict potato yield before the second hilling (6‐8 leaf stage)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Holland Scientific Crop Circle™ ACS‐430 (HCCACS‐430) sensor
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Weather data (precipitation variations)
Number of subjects: 2
Study: 26080338

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (intravenous ertapenem 1 g/d for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Surgical treatment (standard open appendectomy)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 530
Study: 23848326

Group type: EXPERIMENTAL
Intervention: Low-cost simulated obstetrical emergencies (PPH or PEC) followed by debriefing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lecture on PPH or PEC
Number of subjects: 20
Study: 22008822

Group type: EXPERIMENTAL
Intervention: PCV13 toddler dose
Number of subjects: 0
Study: 20107684

Group type: EXPERIMENTAL
Intervention: Beverage mixed with 25 g of rapadura and 40 mg of ascorbic acid (per 200-mL serving)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beverage sweetened with 25 g of standard refined sugar and 40 mg of ascorbic acid (per 200-mL serving)
Number of subjects: 0
Study: 16437248

Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Capsaicin instillation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EMDA
Number of subjects: 52
Study: 15639694

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/d
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 1024
Study: 15546223

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (20 min a day for 3 days)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nonemotional topic writing (control group)
Number of subjects: 104
Study: 11005269

Group type: EXPERIMENTAL
Intervention: GH replacement therapy for 6 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GH replacement therapy for 12 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 31
Study: 8938539

Group type: EXPERIMENTAL
Intervention: HBsAg-negative blood transfusion
Number of subjects: 41
Study: 1603340

Group type: EXPERIMENTAL
Intervention: Epitol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tegretol
Number of subjects: 40
Study: 3086024

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 51Cr‐EDTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L‐rhamnose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG‐400
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetrimide and hyperosmolar stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactulose and 51Cr‐EDTA
Number of subjects: 0
Study: 3419838

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (US) at 0.1 W/cm2
Number of subjects: 125

Group type: COMPARATOR
Intervention: 'Mock' US with massage
Number of subjects: 125

Group type: COMPARATOR
Intervention: 'Mock' US without massage
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Self-massage with a dummy applicator
Number of subjects: 125

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 125
Study: 30817467

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study: 27554689

Group type: EXPERIMENTAL
Intervention: Thigh-high 30-40 mm Hg compression therapy for 7 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: No compression therapy
Number of subjects: 70
Study: 25743602

Group type: EXPERIMENTAL
Intervention: Dancesport training program (16 weeks, 32 hours total)
Number of subjects: 686
Study: 23883571

Group type: EXPERIMENTAL
Intervention: Hypocaloric IV nutrition (50% of measured energy expenditure)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normocaloric IV nutrition (100% of measured energy expenditure)
Number of subjects: 16
Study: 21310898

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no physical therapy)
Number of subjects: 91
Study: 19930281

Group type: EXPERIMENTAL
Intervention: Self-reported sleep disturbance and fatigue severity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Actigraphy measurements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-reported depressive symptoms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medical Outcomes Short Form-36, version 2
Number of subjects: 20
Study: 17485645

Group type: EXPERIMENTAL
Intervention: Recovery from moderate disability (mRS 3)
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Recovery from severe disability (mRS 4)
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Recovery from very severe disability (mRS 5)
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Overall recovery from disability (mRS > or = 3)
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Predictors of recovery
Number of subjects: 1662
Study: 16213869

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen alone or combined with medroxyprogesterone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (dosage not specified)
Number of subjects: 0
Study: 11570651

Group type: EXPERIMENTAL
Intervention: Intervention based on social‐cognitive theory to reduce sexual HIV risk behaviors
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 3706
Study: 10181028

Group type: EXPERIMENTAL
Intervention: Informed Group (IG) with self-report and weight measurement + six body weighing habit items
Number of subjects: 223

Group type: COMPARATOR
Intervention: Uninformed Group (UG) with self-report and weight measurement + one body weight item
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Informed Group (IG)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Uninformed Group (UG)
Number of subjects: 223
Study: 7848946

Group type: EXPERIMENTAL
Intervention: Catheter with a terminal hole
Number of subjects: 200

Group type: COMPARATOR
Intervention: Catheter with three lateral eyes
Number of subjects: 200
Study: 3389864

Group type: EXPERIMENTAL
Intervention: Oxandrolone, 2.5 mg per day (mean dose 0.072 mg/kg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxandrolone, 2.5 mg per day (mean dose 0.073 mg/kg/day) after placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxandrolone treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study: 31199462

Group type: EXPERIMENTAL
Intervention: methylphenidate (0.3 mg/kg, twice a day for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 28196787

Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention (BAI)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (no inhibitory training)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Beer‐NoGo (inhibit responses linked to task‐irrelevant pictures of beer)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Restrained‐Stop (requiring more urgent inhibition but without pictures of beer)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combined (urgent inhibition to pictures of beer)
Number of subjects: 114
Study: 26386850

Group type: EXPERIMENTAL
Intervention: Argus I epiretinal prosthesis
Number of subjects: 1
Study: 23927594

Group type: EXPERIMENTAL
Intervention: Cynatine® FLX (500 mg per day for 60 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, identical dosage for 60 days)
Number of subjects: 50
Study: 22114283

Group type: EXPERIMENTAL
Intervention: Multivoxel pattern analysis (MVPA) applied to fMRI data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVPA in parieto-frontal regions
Number of subjects: 0

Group type: COMPARATOR
Intervention: MVPA compared to traditional fMRI analysis techniques
Number of subjects: 0
Study: 19131065

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg)
Number of subjects: 30
Study: 16702006

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at an initial dose of 0.003 mg/kg/day for 4 weeks, increased to 0.006 mg/kg/day for 4 weeks, and then to 0.012 mg/kg/day for the last 16 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 73
Study: 15085496

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 microg every 4 hours followed by oxytocin if indicated)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Intracervical Foley catheter with simultaneous use of oxytocin
Number of subjects: 162

Group type: COMPARATOR
Intervention: Foley/oxytocin
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 162
Study: 11322670

Group type: EXPERIMENTAL
Intervention: Pharmacy discharge plan intervention
Number of subjects: 362

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 362
Study: 9479601

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 80
Study: 7947061

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional dressing and compression therapy
Number of subjects: 70
Study: 3115449

Group type: EXPERIMENTAL
Intervention: Lactulose for four days before admission
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31791380

Group type: EXPERIMENTAL
Intervention: Individualised behaviour change strategies delivered by neurophysiotherapists over a 12-month period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care during the 12-month study period.
Number of subjects: 0
Study: 27787443

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab plus DHA (1,050 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab alone
Number of subjects: 62
Study: 26457142

Group type: EXPERIMENTAL
Intervention: Adaptive longitudinal online curriculum in bone health
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard curriculum in bone health care alone
Number of subjects: 50
Study: 24141644

Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary psycho‐oncological approach (IPA)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Structured anaesthesiology interview group (SAI)
Number of subjects: 251
Study: 20674911

Group type: EXPERIMENTAL
Intervention: E(2) + P
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: hCG + P
Number of subjects: 288

Group type: COMPARATOR
Intervention: P only
Number of subjects: 288
Study: 19653341

Group type: EXPERIMENTAL
Intervention: Imipramine (25 mg, allowed to double at week 2 if needed)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 17876402

Group type: EXPERIMENTAL
Intervention: aMCI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mild AD
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal Controls
Number of subjects: 45
Study: 15113952

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (120 mg iron as ferrous sulfate and 0.5 mg folic acid)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Twice weekly iron supplementation (60 mg iron and 0.25 mg folic acid)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Twice weekly iron supplementation
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation
Number of subjects: 116
Study: 11306774

Group type: EXPERIMENTAL
Intervention: Amantadine (500 ml i.v. daily for 5 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9522320

Group type: EXPERIMENTAL
Intervention: cyproterone acetate (5 mg p.o.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nomegestrol acetate (5 mg p.o.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: progesterone (100 mg, vaginal cream)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy fertile women, n = 8)
Number of subjects: 30
Study: 7699945

Group type: EXPERIMENTAL
Intervention: HLBI-VCAP combination therapy (Interferon-alpha + VCAP chemotherapy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: VCAP chemotherapy alone
Number of subjects: 28
Study: 2892699

Group type: EXPERIMENTAL
Intervention: ferrous gluconate
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 14
Study: 30536293

Group type: EXPERIMENTAL
Intervention: Non-suicidal self-injury (nssi)
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Risk factors for nssi
Number of subjects: 1326
Study: 27806875

Group type: EXPERIMENTAL
Intervention: High dose vitamin D3 supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24687891

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous device-aided drug delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-pharmacological approaches
Number of subjects: 0
Study: 22013099

Group type: EXPERIMENTAL
Intervention: 15 g alcohol/d
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 30 g alcohol/d
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nonalcoholic placebo beverage
Number of subjects: 51
Study: 20013463

Group type: EXPERIMENTAL
Intervention: Eccentric exercise on elbow flexors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eccentric exercise on knee flexors
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eccentric exercise on both elbow and knee flexors
Number of subjects: 12
Study: 17638583

Group type: EXPERIMENTAL
Intervention: GLOA (buprenorphine injection to the stellate ganglion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSB (saline injection to the stellate plus intramuscular buprenorphine)
Number of subjects: 0
Study: 16036498

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 45
Study: 12435014

Group type: EXPERIMENTAL
Intervention: Glass ionomer luting cement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zinc phosphate luting cement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zinc polycarboxylate luting cement
Number of subjects: 20
Study: 10492735

Group type: EXPERIMENTAL
Intervention: Questionnaire measuring condom use in the last 10 coital acts
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Retrospective log of coital acts in the past two weeks
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Questionnaires based on the past month or six months
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Use with partners who were not clients
Number of subjects: 2266
Study: 8756806

Group type: EXPERIMENTAL
Intervention: Oxygen monotherapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: NPPV
Number of subjects: 12

Group type: COMPARATOR
Intervention: NPPV plus O2 therapy
Number of subjects: 12
Study: 1348473

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (20 mg daily)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 2865921

Group type: EXPERIMENTAL
Intervention: High-dose ketoconazole (800 mg/d)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Low-dose ketoconazole (400 mg/d)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Both low-dose and high-dose ketoconazole
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Ketoconazole (both doses)
Number of subjects: 134
Study: 31290983

Group type: EXPERIMENTAL
Intervention: Targeted insulin-adherence interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29385640

Group type: EXPERIMENTAL
Intervention: Diazoxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25262177

Group type: EXPERIMENTAL
Intervention: IV hydrocortisone (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22953792

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including interactive training and a software programme for dose adjustment
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 404
Study: 20701547

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 8 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 10 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 12 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum pressure of 14 mm Hg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Duration of operation >45 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraoperative analgesics
Number of subjects: 100

Group type: COMPARATOR
Intervention: Use of drains
Number of subjects: 100
Study: 18028738

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (150 mg/day for 5 days starting from day 3 of cycle)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (normoovulatory obese women)
Number of subjects: 68
Study: 15756629

Group type: EXPERIMENTAL
Intervention: Salmeterol-fluticasone combination (50 mcg salmeterol plus 500 mcg fluticasone, twice daily)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Standard treatment (inhaled steroid 1,000 mcg BDP equivalent plus LABA and/or theophylline and/or montelukast)
Number of subjects: 231
Study: 11944382

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg twice daily (Group II)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Endoscopic low-intensity laser irradiation (LILI) for 5 min, 6 to 8 procedures (Group III)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional therapy (Group I)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (7 healthy subjects)
Number of subjects: 130